Signals, Powered By EquityPandit
Cadila Healthcare has got the Establishment Inspection Report (EIR) for its Changodar manufacturing plant that is located near Ahmedabad, from the US health regulator after successful completion of inspection.
Cadila has said in a BSE filing that “The company’s Topical manufacturing facility located at Changodar, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in March 2016.”
It has said further that “The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant.”
The FDA, after the completion of inspection, has provided an Establishment Inspection Report to an establishment.
